Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy.
Remission rates for patients with acute promyelocytic leukemia (APL) have improved with the use of anthracyclines and proper management of disseminated intravascular coagulopathy. In a prospective randomized trial of chemotherapy in patients with acute nonlymphoblastic leukemia, there were 16 patients with APL. All 7 of the patients receiving the amsacrine-containing regimen and 5 of 9 receiving the daunorubicin-containing regimen achieved a remission. All patients, except 2 of the 3 who underwent bone marrow transplantation, remain alive and in remission from 1+ to 25+ mo. Amsacrine is an effective replacement for daunorubicin in the treatment of APL, and its use does not compromise the favorable remission duration characteristic of APL.
D000328:Adult; D000368:Aged; D000609:Aminoacridines / Q000008:administration & dosage; D000677:Amsacrine; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003630:Daunorubicin / Q000008:administration & dosage; D004211:Disseminated Intravascular Coagulation / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged
D000609:Aminoacridines; D000903:Antibiotics, Antineoplastic; D000677:Amsacrine; D003630:Daunorubicin